Anti-IgE Therapy with Omalizumab for Severe Asthma: Current Concepts and Potential Developments

Publisher： Bentham Science Publishers

E-ISSN： 1873-5592|16|2|171-178

ISSN： 1389-4501

Source： Current Drug Targets, Vol.16, Iss.2, 2015-02, pp. : 171-178

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anti-IgE monoclonal antibody, omalizumab: a new treatment for allergic asthma

By Chung K Fan  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 2, 2004-02 ,pp. : 439-446

Informa Healthcare

Access to resources Recommend Favorite

Anti-IgE Therapy in Allergic Asthma

By  

Current Drug Targets. Inflammation & Allergy, Vol. 4, Iss. 5, 2005-10 ,pp. : 551-564

Bentham Science Publishers

Access to resources Recommend Favorite

Anti-IgE Monoclonal Antibody (Omalizumab) in the Treatment of Atopic Asthma and Allergic Respiratory Diseases

By  

Current Drug Targets. Inflammation & Allergy, Vol. 3, Iss. 3, 2004-09 ,pp. : 227-229

Bentham Science Publishers

Access to resources Recommend Favorite

Anti-IgE monoclonal antibody E25 beneficial in allergic asthma

By  

Inpharma, Vol. 1, Iss. 1220, 2000-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Omalizumab is an effective add-on therapy in moderate-to-severe allergic asthma

By Adis International Limited  

Drugs & Therapy Perspectives, Vol. 21, Iss. 7, 2005-07 ,pp. : 1-4

Adis International

Access to resources Recommend Favorite